Brian C. Betts

Has grant

Vice Chair

Roswell Park Comprehensive Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

JAK2_STAT3 as a therapeutic target and marker of graft-versus-host disease

Open Date: 2013-08-10

Close Date: 2018-05-31

Articles (2)

Purpose: Acute and chronic GVHD remain major causes of transplant-related morbidity and mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). We have shown CD83 chimeric antigen receptor (CAR) T cells prevent GVHD and kill myeloid leukemia cell lines. In this pilot study, we investigate CD83 expression on GVHD effector cells, correlate these discoveries with clinical outcomes, and evaluate critical therapeutic implications for transplant recipients. Experimental Design: CD83 expression was evaluated among circulating CD4 + T cells, B-cell subsets, T follicular helper (Tfh) cells, and monocytes from patients with/without acute or chronic GVHD ( n = 48 for each group), respectively. CD83 expression was correlated with survival, TRM, and relapse after alloHCT. Differential effects of GVHD therapies on CD83 expression was determined. Results: CD83 overexpression on CD4 + T cells correlates with reduced survival and increased TRM. Increased CD83 + B cells and Tfh cells, but not monocytes, are associated with poor posttransplant survival. CD83 CAR T eliminate autoreactive CD83 + B cells isolated from patients with chronic GVHD, without B-cell aplasia as observed with CD19 CAR T. We demonstrate robust CD83 antigen density on human acute myeloid leukemia (AML), and confirm potent antileukemic activity of CD83 CAR T in vivo , without observed myeloablation. Conclusions: CD83 is a promising diagnostic marker of GVHD and warrants further investigation as a therapeutic target of both GVHD and AML relapse after alloHCT.

Year:

2025

Purpose: Acute and chronic GVHD remain major causes of transplant-related morbidity and mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). We have shown CD83 chimeric antigen receptor (CAR) T cells prevent GVHD and kill myeloid leukemia cell lines. In this pilot study, we investigate CD83 expression on GVHD effector cells, correlate these discoveries with clinical outcomes, and evaluate critical therapeutic implications for transplant recipients. Experimental Design: CD83 expression was evaluated among circulating CD4+ T cells, B-cell subsets, T follicular helper (Tfh) cells, and monocytes from patients with/without acute or chronic GVHD (n = 48 for each group), respectively. CD83 expression was correlated with survival, TRM, and relapse after alloHCT. Differential effects of GVHD therapies on CD83 expression was determined. Results: CD83 overexpression on CD4+ T cells correlates with reduced survival and increased TRM. Increased CD83+ B cells and Tfh cells, but not monocytes, are associated with poor posttransplant survival. CD83 CAR T eliminate autoreactive CD83+ B cells isolated from patients with chronic GVHD, without B-cell aplasia as observed with CD19 CAR T. We demonstrate robust CD83 antigen density on human acute myeloid leukemia (AML), and confirm potent antileukemic activity of CD83 CAR T in vivo, without observed myeloablation. Conclusions: CD83 is a promising diagnostic marker of GVHD and warrants further investigation as a therapeutic target of both GVHD and AML relapse after alloHCT.

Year:

2023

Collaborators (12)

Joseph Maakaron

Assistant Professor

University of Minnesota

UNITED STATES
View details

Daniel Weisdorf

Faculty, Leader

University of Minnesota

UNITED STATES
View details

Najla El Jurdi

Assistant Professor

University of Minnesota

UNITED STATES
View details

Marco Davila

SVP, Translational Research

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Margaret MacMillan

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Bruce Blazar

Regents Professor

University of Minnesota

UNITED STATES
View details

Veronika Bachanova

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Connor Demorest

University of Minnesota

UNITED STATES
View details

Martin Felices

Associate Professor

University of Minnesota

UNITED STATES
View details

Jeffrey S Miller

University of Minnesota System

UNITED STATES
View details

Anne Eaton

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Shernan Holtan

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details